Augustine Therapeutics Appoints Rie Schultz Hansen As Chief Scientific Officer

May 21, 2025•about 2 months ago

Position

Chief Scientific Officer

Company

Augustine Therapeutics

Rie Schultz Hansen

LeuvenTherapeuticsBiotechnology

Description

Augustine Therapeutics announces the appointment of Rie Schultz Hansen, PhD, as Chief Scientific Officer. This hiring is effective immediately and aims to strengthen the company's leadership in advancing its HDAC6 inhibitor program.

Company Information

Company

Augustine Therapeutics

Location

Leuven, Flemish Brabant, Belgium

About

Augustine Therapeutics is a pioneering biotech company focused on developing best-in-class, novel, potent and subtype-selective small-molecule inhibitors for neurodegenerative and cardiometabolic diseases. The company's unique pipeline aims to achieve meaningful benefits for patients with neurodegenerative and cardiometabolic diseases through the development of potential breakthrough therapeutics.

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months

Related People

Augustine Therapeutics Appoints Rie Schultz Hansen As Chief Scientific Officer

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Executive Insights

Related People

Gerhard hidden

Carl hidden

Virginie hidden

Company Information